The five select Pfizer products to be included in the specialty distribution are: Bosulif (bosutinib), Ibrance (palbociclib), Inlyta (axitinib), Sutent (sunitinib malate) and Xalkori (crizotinib).
Bosulif is used to treat chronic myelogenous leukemia; Ibrance treats advanced breast cancer; Inlyta and Sutent are given to patients with kidney cancer; and Xalkori is used to treat non-small cell lung cancer.
"We are proud to be included in Pfizer's limited-distribution network for these five important treatments," Jim Fox, CEO of the Excelera Network, said. "Excelera’s model of health system-based specialty pharmacies, integrated at the point of patient care, is ideal for ensuring appropriate utilization of these limited distribution therapies with the highest standards of quality and safety."
Albert Zimmerli, chairman of Excelera's board and executive vice president and chief financial officer for Intermountain Healthcare, said that the selection of Excelera as a specialty distribution outlet allows Intermountain Healthcare and other member health systems to provide the highest standards of care for patients who need the five crucial medications.
ExceleraRx Corp. is a national network of specialty pharmacies at health systems and academic medical centers. It allows member organizations access to restricted payer agreements and limited distribution drugs.
Alerts Sign-up